vTv Therapeutics to Participate in 7th Annual Evercore HealthCONx Conference HIGH POINT, N.C., Dec. 02, 2024 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company with a portfolio of novel small molecules and a lead program in diabetes, today announced that management will participate in a fireside chat and be available for one-on-one meetings at the 7th Annual Evercore HealthCONx Conference to be held in Coral Gables. Florida, December 3 – 5, 2024. 7th Annual Evercore HealthCONx Conference Presentation Date:December 4, 2024 Time:7:55 – 8:1...
Moody's Ratings (Moody's) has completed a periodic review of the ratings of Eaton Vance Limited Duration Income Fund and other ratings that are associated with this issuer. The review was conducted through a rating committee held on 21 November 2024 in which we reassessed the appropriateness of the...
A director at Vtv Therapeutics Inc maiden bought 5,000 shares at 16.762USD and the significance rating of the trade was 58/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two ...
vTv Therapeutics Announces 2024 Third Quarter Financial Results and Provides Corporate Update HIGH POINT, N.C., Nov. 12, 2024 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company with a portfolio of novel small molecules and a lead program in diabetes, today reported financial results for the third quarter ended September 30, 2024, and provided an update on recent corporate developments. "Our cadisegliatin program continues to show promise as a new oral adjunct therapy being investigated for improvement in glycemic control and red...
Still No Decisive Breakout as SPX Tests 5783 The S&P 500 (SPX) remains just below 5783, which is the upper-end of an important target/resistance area we have discussed for over a month (5670-5783). 5670 was the prior all-time high set in July, while 5783 is 2% above 5670. It is hard to call it a "decisive" breakout if the SPX is not even 2% above its prior high, and, importantly, in 2007, the SPX made a top after climbing 1-2% above its prior high. To reiterate, the 2007 topping analog has trac...
vTv Therapeutics Announces 2024 Second Quarter Financial Results and Provides Corporate Update Screened first patient in cadisegliatin pivotal trial for type 1 diabetes (T1D); working to resolve clinical hold Expanded Newsoara Biopharma license agreement for PDE4 inhibitor HPP737 to a global license effective upon payment of the $20 million upfront fee HIGH POINT, N.C., Aug. 08, 2024 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company with an innovative clinical portfolio of small molecules and lead program in diabetes, today reported fin...
vTv Therapeutics Announces Cadisegliatin Program for Type 1 Diabetes Placed on Clinical Hold HIGH POINT, N.C., July 26, 2024 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late stage biopharmaceutical company with an innovative clinical portfolio of small molecules and lead program in diabetes, today announced that the United States Food and Drug Administration (FDA) has placed a clinical hold on the cadisegliatin clinical program which includes the ongoing CATT1 Phase 3 trial in type 1 diabetes. Cadisegliatin is an oral, liver selective, glucokinase activator that has been w...
vTv Therapeutics Announces Screening of First Patient in CATT1 Pivotal Trial Evaluating Cadisegliatin for Type 1 Diabetes Cadisegliatin is a potential first-in-class oral liver selective glucokinase activator for T1D, which has been granted Breakthrough Therapy designation by the FDA for T1D Cadisegliatin has been dosed in over 500 subjects to date, including 300 patients with diabetes HIGH POINT, N.C., June 24, 2024 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late stage biopharmaceutical company with an innovative clinical portfolio of small molecules and lead program i...
vTv Therapeutics Announces 2024 First Quarter Financial Results and Provides Corporate Update HIGH POINT, N.C., May 09, 2024 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of an adjunctive therapy to insulin for the treatment of type 1 diabetes ("T1D"), today reported financial results for the first quarter ended March 31, 2024, and provided an update on recent corporate developments. “The first quarter of 2024 saw us reach several important milestones, which we believe position vTv well for continued execut...
vTv Therapeutics Announces 2023 Fourth Quarter and Full Year Financial Results and Provides Corporate Update Recently completed $51 million PIPE from healthcare-focused institutional investors and the JDRF T1D Fund.Company's first Phase 3 clinical trial of cadisegliatin (TTP399), an oral adjunctive therapy to insulin, for the treatment of type 1 diabetes, expected to initiate patient enrollment in the second quarter of 2024.In connection with the PIPE, vTv has reduced the size of its Board of Directors from nine to seven members. Three of the Board members will be designated by the new ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.